Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

LEO Pharma: Clinical Trials & FDA Approval Profile

LEO Pharma (Global / Institutional) sponsors 33 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (4 recruiting now), 25 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.1%
Median Closed Enrollment vs National (145 pts)215 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for LEO Pharma
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)33
Active Pipeline (Recruiting Now)5 (4)
Completed vs Stopped Early25 / 3 (9.1%)
Median Closed Actual Enrollment215 participants
Physical Hospital Site Disclosure25.4% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With LEO Pharma
Hospital Research SiteLocationShared Protocols
Mount Sinai Hospital and Icahn School of MedicineNew York, NY3
Charité Universitätsmedizin BerlinBerlin3
The Second Affiliated Hospital Zhejiang University School of MedicineHangzhou, Zhejiang2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by LEO Pharma
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06624670A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumPhase IIIRECRUITING
NCT03886246Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a PreviousPhase IIACTIVE NOT RECRUITING
NCT05295732The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI IchthyosisPhase IIICOMPLETED
NCT04154293A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital IchthyosisPhase IICOMPLETED
NCT03395132Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang BeisoPhase IIITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the LEO Pharma Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI